C4 Therapeutics (CCCC) announced the appointment of Owen Hughes to its board of directors. Hughes is an accomplished life sciences executive with nearly three decades of experience in investing, operations and corporate governance. Hughes most recently served as co-founder and chief executive officer of Cullinan Oncology (CGEM)
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CCCC:
- C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
- C4 Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley
- C4 Therapeutics price target lowered to $7 from $17 at H.C. Wainwright
- C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics reports Q3 EPS (55c), consensus (66c)